UAEM - Licensing and patenting practices of COVID-19 technologies

Sarai Keestra made this Freedom of Information request to Cambridge Enterprise Limited

Automatic anti-spam measures are in place for this older request. Please let us know if a further response is expected or if you are having trouble responding.

The request was successful.

Dear Cambridge Enterprise Limited,

For the purpose of clarity, please adhere to the following definitions when answering these questions:

Definitions
Low and middle income country: A country that is defined as ‘low’, ‘lower-middle’ and ‘upper-middle’ income by the World Bank for the year 2018. Income status defined by GNI per capita.
Source: World bank, available online [https://tinyurl.com/y5dwc2qv]
A patent grants an inventor the exclusive rights to his or her invention. A patent holder can stop other people from selling, manufacturing, producing, or using the invention for a certain period of time.
Source: Upcouncil, available online [https://www.upcounsel.com/what-is-a-pate...

Licence: Permission for the licensee to use the intellectual property rights
Source: TaylorWessing, available online [https://www.taylorwessing.com/download/a...

Exclusive Licence: A licence that allows only the named licensee to exploit the relevant IP rights, the licensor is also excluded from exploiting these IP rights.

Non-Exclusive Licence: A licence that grants any number of licensees to exploit the IP.
Source: TaylorWessing, available online [https://www.taylorwessing.com/synapse/co...

Health Technology: ‘Health technology as defined by the WHO: “A health technology is the application of organized knowledge and skills in the form of devices, medicines, vaccines, procedures and systems developed to solve a health problem and improve quality of lives.’
Source: WHO, available online [https://www.who.int/health-technology-as...

START FOI request:
Q1. Can you release your internal strategy regarding licensing and patenting of COVID-19 related health technologies?

Q2. Does the institution have a formal policy on licensing and patenting of COVID-19 related technologies? If yes, please provide a link or PDF to the relevant policy document.

Q3. Has the university considered updating their strategy regarding the licensing and patenting of health technologies since the start of the pandemic?

Q4. Please provide an Excel spreadsheet with headings as displayed below with all the COVID-19 related health technologies LICENSED by the university AND specify which countries they were licensed in AND specify whether they are exclusive or non-exclusive licenses.
Health Technology Licensed | Country of Licensing | Type of License (Exclusive or Non-Exclusive)

Q5. Please provide a list of patents granted to your organization for any COVID-19 related health technologies listed by patent family, indicating countries/regions in which the patent has been granted.

Q6. Does the institution have any plans on signing up to the Open-COVID pledge (https://opencovidpledge.org/) or any similar initiative that seeks to minimise intellectual property rights barriers during the COVID-19 pandemic? If yes, please specify.

Q7. Is the institution considering the licensing of COVID-19 related health technologies to the Covid Technology Access Pool (C-TAP) or the Medicines Patent Pool (MPP) during the pandemic? If yes, please specify.

END FOI request.
If you have any questions please do not hesitate to contact me by email.

Yours faithfully,

Sarai Keestra

Dear Cambridge Enterprise Limited,

I would like to remind you to respond to my FOI request, which is by now delayed. I would be grateful for a response before Christmas if possible. Have a good holiday!

Yours faithfully,

Sarai Keestra

Paul J. Seabright, Cambridge Enterprise Limited

3 Attachments

Dear Sairai

 

We received a request from [1][email address]
on the 13 November 2020 19:49. I replied to the same e-mail address at Fri
11/12/2020 10:47 as you see below.

 

 

Unfortunately, I now see that Outlook did not recognise the e-mail address
so the e-mail has now been resent.

 

 

Thank you for following up. Please do not hesitate to contact me if our
response has not been received.

 

Merry Christmas

 

Paul

 

 

[2]UofC Enterprise Logo.png Dr Paul Seabright

Deputy Director

Mobile: +44 (0)7706 684527

 

Everybody at Cambridge Enterprise is now working from home, using our
established and secure cloud-based systems. While we aim to provide a
normal service, individual working patterns may vary in order to allow for
home life, so please bear with us if we’re not immediately available.
Thank you for your understanding.

 

 

 

 

show quoted sections

Dear Paul J. Seabright,

Appologise for the confusion. I have now realised that my colleague sent an FOI request with a similar title on the same day. Please find here the history of this particular request: https://www.whatdotheyknow.com/request/u...
We both use the same publicly accessible website (what do they know .com) to send FOI requests, this is why it looks like it comes from the same email address, even if it is different requests from different people! I hope I have hereby clarified the request. Please note that my FOI request is different from Alice's, which I have seen that you responded to. I have copied out the request again below, my request relates specifically to COVID-19 related health technologies only and is also for a different time period. If you would have time to look at it the earliest possible I would be very grateful. Have a good Christmas and a happy 2021!

Yours sincerely,

Sarai Keestra

START FOI request:
Q1. Can you release your internal strategy regarding licensing and patenting of COVID-19 related health technologies?

Q2. Does the institution have a formal policy on licensing and patenting of COVID-19 related technologies? If yes, please provide a link or PDF to the relevant policy document.

Q3. Has the university considered updating their strategy regarding the licensing and patenting of health technologies since the start of the pandemic?

Q4. Please provide an Excel spreadsheet with headings as displayed below with all the COVID-19 related health technologies LICENSED by the university AND specify which countries they were licensed in AND specify whether they are exclusive or non-exclusive licenses.
Health Technology Licensed | Country of Licensing | Type of License (Exclusive or Non-Exclusive)

Q5. Please provide a list of patents granted to your organization for any COVID-19 related health technologies listed by patent family, indicating countries/regions in which the patent has been granted.

Q6. Does the institution have any plans on signing up to the Open-COVID pledge (https://opencovidpledge.org/) or any similar initiative that seeks to minimise intellectual property rights barriers during the COVID-19 pandemic? If yes, please specify.

Q7. Is the institution considering the licensing of COVID-19 related health technologies to the Covid Technology Access Pool (C-TAP) or the Medicines Patent Pool (MPP) during the pandemic? If yes, please specify.

END FOI request.

For the purpose of clarity, please adhere to the following definitions when answering these questions:
Definitions
Low and middle income country: A country that is defined as ‘low’, ‘lower-middle’ and ‘upper-middle’ income by the World Bank for the year 2018. Income status defined by GNI per capita.
Source: World bank, available online [https://tinyurl.com/y5dwc2qv]
A patent grants an inventor the exclusive rights to his or her invention. A patent holder can stop other people from selling, manufacturing, producing, or using the invention for a certain period of time.
Source: Upcouncil, available online [https://www.upcounsel.com/what-is-a-pate...
Licence: Permission for the licensee to use the intellectual property rights
Source: TaylorWessing, available online [https://www.taylorwessing.com/download/a...
Exclusive Licence: A licence that allows only the named licensee to exploit the relevant IP rights, the licensor is also excluded from exploiting these IP rights.
Non-Exclusive Licence: A licence that grants any number of licensees to exploit the IP.
Source: TaylorWessing, available online [https://www.taylorwessing.com/synapse/co...
Health Technology: ‘Health technology as defined by the WHO: “A health technology is the application of organized knowledge and skills in the form of devices, medicines, vaccines, procedures and systems developed to solve a health problem and improve quality of lives.’
Source: WHO, available online [https://www.who.int/health-technology-as...

Paul J. Seabright, Cambridge Enterprise Limited

Sarai
Our office is now pretty much closed until Jan 4. Are you happy to wait
for us to start auctioning your request until we return in the New Year?
Paul
Get [1]Outlook for iOS

--------------------------------------------------------------------------

From: Sarai Keestra <[FOI #706977 email]>
Sent: Friday, December 18, 2020 4:55:42 PM
To: Paul J. Seabright <[email address]>
Subject: RE: Freedom of Information request - UAEM - Licensing and
patenting practices of COVID-19 technologies
 
Dear Paul J. Seabright,

Appologise for the confusion. I have now realised that my colleague sent
an FOI request with a similar title on the same day. Please find here the
history of this particular request:
[2]https://www.whatdotheyknow.com/request/u...

We both use the same publicly accessible website (what do they know .com)
to send FOI requests, this is why it looks like it comes from the same
email address, even if it is different requests from different people! I
hope I have hereby clarified the request. Please note that my FOI request
is different from Alice's, which I have seen that you responded to. I have
copied out the request again below, my request relates specifically to
COVID-19 related health technologies only and is also for a different time
period. If you would have time to look at it the earliest possible I would
be very grateful. Have a good Christmas and a happy 2021!

Yours sincerely,

Sarai Keestra

START FOI request:

Q1. Can you release your internal strategy regarding licensing and
patenting of COVID-19 related health technologies?

Q2. Does the institution have a formal policy on licensing and patenting
of COVID-19 related technologies?  If yes, please provide a link or PDF to
the relevant policy document.

Q3. Has the university considered updating their strategy regarding the
licensing and patenting of health technologies since the start of the
pandemic?

Q4. Please provide an Excel spreadsheet with headings as displayed below
with all the COVID-19 related health technologies LICENSED by the
university AND specify which countries they were licensed in AND specify
whether they are exclusive or non-exclusive licenses.

Health Technology Licensed | Country of Licensing | Type of License
(Exclusive or Non-Exclusive)

Q5. Please provide a list of patents granted to your organization for any
COVID-19 related health technologies listed by patent family, indicating
countries/regions in which the patent has been granted.

Q6. Does the institution have any plans on signing up to the Open-COVID
pledge ([3]https://opencovidpledge.org/) or any similar initiative that
seeks to minimise intellectual property rights barriers during the
COVID-19 pandemic? If yes, please specify.

Q7. Is the institution considering the licensing of COVID-19 related
health technologies to the Covid Technology Access Pool (C-TAP) or the
Medicines Patent Pool (MPP) during the pandemic? If yes, please specify.

END FOI request.

For the purpose of clarity, please adhere to the following definitions
when answering these questions:

Definitions

Low and middle income country: A country that is defined as ‘low’,
‘lower-middle’ and ‘upper-middle’ income by the World Bank for the year
2018. Income status defined by GNI per capita.

Source: World bank, available online [[4]https://tinyurl.com/y5dwc2qv]

A patent grants an inventor the exclusive rights to his or her invention.
A patent holder can stop other people from selling, manufacturing,
producing, or using the invention for a certain period of time.

Source: Upcouncil, available online
[[5]https://www.upcounsel.com/what-is-a-pate...

Licence: Permission for the licensee to use the intellectual property
rights

Source: TaylorWessing, available online
[[6]https://www.taylorwessing.com/download/a...

Exclusive Licence: A licence that allows only the named licensee to
exploit the relevant IP rights, the licensor is also excluded from
exploiting these IP rights.

Non-Exclusive Licence: A licence that grants any number of licensees to
exploit the IP.

Source: TaylorWessing, available online
[[7]https://www.taylorwessing.com/synapse/co...

Health Technology: ‘Health technology as defined by the WHO: “A health
technology is the application of organized knowledge and skills in the
form of devices, medicines, vaccines, procedures and systems developed to
solve a health problem and improve quality of lives.’

Source: WHO, available online
[[8]https://www.who.int/health-technology-as...

show quoted sections

Dear Paul J. Seabright,

Yes, if you office is closed until after the 4th that is fine with us of course. If you would be able to respond by the 11th though we would be very grateful, as this will ensure we can integrate the University of Cambridge responses in our comparative analysis.
I am wishing you a very healthy 2021!

Yours sincerely,

Sarai Keestra

Paul J. Seabright, Cambridge Enterprise Limited

Thank you for your message.

I am am out of the office until 04-01-2021.

I will check my e-mail periodically but replies may not be as timely as
normal.

Urgent enquiries please contact Carol Harrison 07551 668290

Cambridge enterprised will be closed from CoB on 23/12/2020 and re-open
again on 04/01/2021

 

 

 

Dear Paul J. Seabright,

Happy new year! I was wondering if you have been able to review our request 'UAEM - Licensing and patenting practices of COVID-19 technologies' as of yet? We are still waiting for your response.

Yours sincerely,

Sarai Keestra

Paul J. Seabright, Cambridge Enterprise Limited

Sarai

I hope to get you an answer to all but the licence question tomorrow morning. We had several key staff off last week and I need them to review the licences before I can complete that question. I hope to be able to answer that remaining question by the middle of the week.

Paul

show quoted sections

Paul J. Seabright, Cambridge Enterprise Limited

1 Attachment

Sarai

As promised here is an interim response. As I said yesterday I am still waiting for key staff input but having reviewed 80+% of last year's licences, so far, we have none that are C-19 related healthcare technologies.

Kind regards
Paul

show quoted sections

Paul J. Seabright, Cambridge Enterprise Limited

1 Attachment

Sarai

Please find attached our complete reply to your questions.

Kind regards
Paul

show quoted sections